New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks ...